To elucidate the cellular mechanism by which angiotensin II (ANG II) induces cardiac hypertrophy, we investigated the possible autocrine/paracrine role of endogenous endothelin-1 (ET-1) in ANG II-induced hypertrophy of neonatal rat cardiomyocytes by use of synthetic ET-1 receptor antagonist and antisense oligonucleotides to preproET-1 (ppET-1) mRNA. Northern blot analysis and in situ hybridization revealed that ppET-1 mRNA was expressed in cardiomyocytes, but, to a lesser extent, in nonmyocytes as well. ANG II upregulated ppET-l mRNA level by threefold over control level as early as 30 min, and it stimulated release of immunoreactive ET-1 from cardiomyocytes in a dose-and time-dependent manner. ET-1 stimulated ppET-1 mRNA levels after 30 min in a similar fashion as ANG II. Tetradecanoylphorbol-acetate (lo-7 M) mimicked the effects of ANG II and ET-1 on induction of ppET-1 mRNA. ANG II-induced ppET-1 gene expression was completely blocked by protein kinase C inhibitor H-7 or by downregulation ofendogenous protein kinase C by pretreatment with phorbol ester. ET-1 and ANG II stimulated twofold increase I13Hlleucine incorporation into cardiomyocytes, whose effects were similarly and dose dependently inhibited by endothelin A receptor antagonist (BQ123). Introduction of antisense sequence against coding region of ppET-l mRNA into cardiomyocytes resulted in complete blockade with ppET-l mRNA levels and 13Hlleucine incorporation stimulated by ANG II. These results suggest that endogenous ET-l locally generated and secreted by cardiomyocytes may contribute to ANG II-induced cardiac hypertrophy via an autocrine / paracrine fashion. (J. Clin. Invest. 1993.92:398403.) Key words: preproendothelin-l mRNA * neonatal rat cardiomyocytes * endothelin A receptor antagonist * antisense nucleotides
Introduction
Endothelin-1 (ET-1)' is a 21-residue vasoconstrictor/vasopressor peptide originally characterized from the supernatant 1 . Abbreviations used in this paper: ANG II, angiotensin II; Ara C, cytosine arabinoside; ET-1, endothelin-1; ET-1 -LI, ET-l-like immunoreactivity; ETA, endothelin A; GADPH, glyceraldehyde-3-phosphate dehydrogenase; NMCs, nonmyocytes; PKC, protein kinase C; ppET-1, preproET-1; SSPE, 0.75 M NaCl/0.05 M NaH2PO4/0.005 M EDTA; TPA, 12-0-tetradecanoylphorbol-1 3-acetate. of cultured porcine aortic endothelial cells ( 1) . This endothelium-derived vasoconstrictive peptide has also been found to be a growth factor in a variety of mammalian cells including vascular smooth muscle cells (2) and fibroblasts (3) . We have recently demonstrated that ET-1 induces hypertrophy of cardiomyocytes in vitro, associated with the induction of muscle specific genes (myosin light chain 2, a-actin, and troponin I) and a protooncogene (c-fos) (4) . Other investigators have also shown that ET-1 is a potent growth factor for cardiomyocytes (5, 6) . Therefore, it is suggested that ET-1 may play an important role in the pathogenesis of cardiac hypertrophy associated with various cardiovascular diseases.
ET-1 is produced not only by vascular endothelial cells, but also by a variety of nonendothelial cells, such as vascular smooth muscle cells (7) , renal epithelial cells (8) , glomerular mesangial cells (9) , and certain cancer cell lines (10) . It has recently been reported that preproET-1 (ppET-1) mRNA is detected in a variety of rat tissue including heart ( 11) . However, no information has yet been available whether ET-1 is produced by cardiomyocytes and acts by themselves in an autocrine and/or paracrine manner.
Angiotensin II (ANG II), on the other hand, is a potent vasoconstrictor hormone that is also involved in cardiac hypertrophy in vitro (12) as well as in vivo (13). To elucidate whether endogenous ET-1 is involved in the mechanism by which ANG II induces cardiac hypertrophy, we investigated the possible autocrine/paracrine role of ET In situ hybridization. Antisense and sense single-strand cRNAs were synthesized from cDNA fragment encoding rat ppET-l subcloned into pBluescript II (Stratagene, La Jolla, CA) in the presence of digoxigenin labeled UTP (Boehringer Mannheim Biochemicals, Indianapolis, IN). The cardiomyocytes plated (Tissue Culture Chambers; Nunc Inc., Roskilde, Denmark) were fixed in 4% paraformaldehyde plus 0.5% glutaraldehyde in PBS, pH 7.4, and incubated with proteinase K (100 ,g/ml, Boehringer Mannheim Biochemicals) in 100 mM Tris HC1, pH 7.6, for 10 min at room temperature. The hybridization buffer contained 0.6M NaCl, 1 mM EDTA, 10 mM Tris HCl, pH 7.6, 10% dextran sulfate, 0.25% SDS, 100 ug/ml transfer RNA, lx Denhardt's solution, 50% (vol/vol) deionized formamide, and labeled denatured probe. Hybridization buffer was applied to each section, followed by incubation in a moist chamber for 16 h at 50°C.
Samples were then incubated with 20 gg/ml RNase A (Boehringer Mannheim Biochemicals) for 30 min at 37°C, followed by washing once with 2X SSC plus 50% formamide for 30 min at 50°C, and twice with 0.2x SSC for 30 min at 50°C. For immunological detection, DIG Nucleicacid Detection Kit from Boehringer Mannheim Biochemicals was used.
RIA. ET-l-like immunoreactivity (ET-1-LI) in media was determined by specific RIA for ET-I as recently reported (20) . The polyclonal antibody used cross-reacted fully with ET-1, 2% with big ET-1, and less than 0.1% with ET-2 and ET-3. In brief, 0.1 ml standard and sample and 0.1 ml antibody (final dilution, 1:150,000) were preincubated at 4°C for 24 h, followed by the addition of0.1 ml [ '25I ] ET-l (specific activity: 2,000 Ci/mmol) (Amersham Japan) and further incubated for 48 h. Separation ofthe bound from free ligand was accomplished by the double antibody method. The sensitivity of ET-l RIA was I fmol/ tube, and the 50% intercept was 14 fmol/tube. The intra-and interassay coefficients ofvariations were 6.9 and 7.3%, respectively. 
Results
As shown in Fig. 1 , abundant amount of ppET-l mRNA was detected in cultured neonatal rat cardiomyocytes incubated with MEM for 24 h. ANG 11 ( 10-6 M) upregulated ppET-I mRNA level by approximately threefold over control level as early as 30 min. ppET-I gene expression then returned to basal level after 2 h and remained constant during 24 h. ET-I ( I0-7 M) also transiently increased the expression of ppET-1 in a similar fashion as ANG II. TPA ( lo-M) mimicked the effects ofANG II and ET-l on induction ofppET-I mRNA. To ascertain that cardiomyocytes indeed express ppET-I mRNA, we performed in situ hybridization using digoxigenin-labeled cRNA sense and antisense probe for ppET-1. The antisenseprobe for ppET-1 strongly hybridized with cardiomyocytes and with NMCs as well (Fig. 2) . Northern blot analysis using cultures ofAra C-treated cardiomyocytes and NMCs revealed that ppET-1 mRNA level in NMCs was lower than that in cardiomyocytes (Fig. 3) .
ANG 11 ( 10-6 M) stimulated ET-1-LI release from cardiomyocytes as early as 60 min and further increased during 24 h (Fig. 4 A) . ANG II dose dependently ( 10 8 M-10-6 M) stimulated ET-1-LI release during 24 h-incubation (Fig. 4 B) .
The ANG II-induced ppET-1 gene expression was completely blocked by a PKC inhibitor H-7 ( I0-5 M), or by down- We next examined the effects of ETA receptor antagonist (BQ123) on ppET-l mRNA levels stimulated by ET-1 and ANG II. The ET-1-stimulated ppET-1 gene expression was completely blocked by BQ123 ( l0-5 M), whereas ANG Il-induced expression ofppET-1 was unaffected by BQ123 (Fig. 6) . The effects of BQ123 on ET-1-and ANG II-induced protein synthesis in rat cardiomyocytes were then examined (Fig. 7) . (Table I ).
To further determine the possible involvement of endogenous ET-1 in ANG II-induced hypertrophy, we introduced antisense oligonucleotides against coding region of ppET-1 mRNA in rat cardiomyocytes and examined the ppET-l mRNA expression and protein synthesis stimulated by ANG II. The antisense sequence ( l0-5 M) blocked ppET-l mRNA (Fig. 8 A) and inhibited the ANG II-induced [3H]leucine incorporation (Fig. 8 B) . The servations led us to speculate that ET-1 may be involved in the development ofcardiac hypertrophy, possibly through the activation of PKC and/or Ca2" mobilization resulting from receptor-mediated phosphoinositide breakdown in cardiomyocytes.
Although ET-1 was originally characterized from the conditioned medium of cultured porcine aortic endothelial cells, recent evidence has revealed that ppET-1 mRNA expression as well as ET-1 is widely distributed in a variety of nonendothelial cells (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The present study demonstrated for the first time that ppET-1 mRNA is abundantly expressed in neonatal rat cardiomyocytes, and ET-1-LI is released into media. These findings verify de novo synthesis and release ofET-1 by cardiomyocytes. Our primary cultures consist mainly of cardiomyocytes, although they contain -20% of NMCs. However, our results by Northern blot analysis that ppET-1 mRNA level in NMCs was lower than that in Ara C-treated cardiomyocytes suggest that the expression of ppET-l mRNA and synthesis and release ofET-1 in our cultures represent mainly the properties of cardiomyocytes.
Genomic cloning of ppET-1 gene (22) Rapid induction ofppET-mRNA was followed by release of ET-1-LI in culture medium, whereas, it continued to increase up to 24 h. This sustained increase in ET-I into culture medium was in agreement with our previous study using bovine endothelial cells (28) , and may be explained by the following reasons: First, it has been suggested that cell-mediated degradation and/or inactivation of ET-may occur little, if any, during incubation with cultured cells (29 10 100-~~~s transcriptional level may be involved (see the review ofHelene and Toulme, reference 30). Although the antisense oligonucleotide used in this study was sensitive to endonuclease, the dose ( 10-5 M) used was two orders greater than the effective dose of the endonuclease sensitive (31 ), thus providing enough, even in the presence of 1% serum. Our results that the antisense sequence, but not the mismatch sequence, against ppET-1 mRNA blocked ANG II-induced protein synthesis lend strong support to the potential contribution of endogenous ET-1 to ANG II-induced cardiac hypertrophy.
In summary, our study has provided evidence that de novo synthesis and release of ET-1 by neonatal rat cardiomyocytes are stimulated by ANG II, possibly through the activation of PKC. Furthermore, our results that ANG II-induced protein synthesis was blocked by ETA receptor antagonist as well as by antisense oligonucleotides against ppET-1 mRNA, suggest the potential role of endogenous ET-1 locally produced and secreted by cardiomyocytes in the mechanism of ANG Il-induced cardiac hypertrophy via an autocrine/paracrine fashion.
